Metabolic Oncology

A 2026 narrative review in Pharmaceuticals (MDPI) and ASCO 2026 real-world data reframe semaglutide's oncogenic and cardiotoxicity profile in quantitative terms. Key figures include a 21% preferential visceral fat reduction, a weight-independent 20% MACE reduction, and 38 to 50% lower metastatic progression rates across four obesity-linked cancers. These numbers shift the risk-benefit calculus decisively toward net benefit for body-composition practitioners.

A 2026 narrative review in Pharmaceuticals (MDPI, DOI: 10.3390/ph19020297) maps semaglutide's pleiotropic effects onto two domains relevant to performance practitioners: oncogenic signalling risk and mitigation of chemotherapy-driven cardiotoxicity. The net oncogenic signal is confounded by obesity itself; the cardiotoxicity mitigation data are preclinical but mechanistically precise. Both domains alter risk stratification for specific user profiles.